Company News: Page (1) of 1 - 06/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research

(June 11, 2018)

NEW YORK, NY, June 11, 2018 (GLOBE NEWSWIRE) -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MEI Pharma (Nasdaq: MEIP), a San Diego-based oncology drug development company with a pipeline of three clinical-stage drug candidates and oncology drug development experience.

The company’s stock has found strength in the recent past. Followed by promising partnerships, well-funded clinical programs, and most recently, promising data at ASCO for ME-401 and the potential for having a best-in-class P13K Delta oral inhibitor. The company’s share price has more than doubled since mid-May after the company announced its clinical data presentations were forthcoming. 

Analyst review, target price and pipeline analysis available here READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/mei/



On June 4th, the company announced that data presented at ASCO 2018 from a Phase 1b study of ME-401, demonstrated a 90% objective response rate in patients with relapsed or refractory follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL). Based on the data in this program, MEI now anticipates progressing into a single-agent registration study later in 2018 for the treatment of adults with relapsed or refractory follicular lymphoma. ME-401 is a next-generation selective oral inhibitor of PI3K delta.

The full MEI report covers earnings data and potential near-term catalysts READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/mei/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


CONTACT: CONTACT:Traders News [email protected]

Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved